The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Noninvasive Radiofrequency Field Destruction of Pancreatic Adenocarcinoma Xenografts Treated with Targeted Gold Nanoparticles
Open accessAbstract
Purpose: Pancreatic carcinoma is one of the deadliest cancers with few effective treatments. Gold nanoparticles (AuNP) are potentially therapeutic because of the safety demonstrated thus far and their physiochemical characteristics. We used the astounding heating rates of AuNPs in nonionizing radiofrequency (RF) radiation to investigate human pancreatic xenograft destruction in a murine model. Experimental Design: Weekly, Panc-1 and Capan-1 human pancreatic carcinoma xenografts in immunocompromised mice were exposed to an RF field 36 hours after treatment (intraperitoneal) with cetuximab- or PAM4 antibody–conjugated AuNPs, respectively. Tumor sizes were measured weekly, whereas necrosis and cleaved caspase-3 were investigated with hematoxylin–eosin staining and immunofluorescence, respectively. In addition, AuNP internalization and cytotoxicity were investigated in vitro with confocal microscopy and flow cytometry, respectively. Results: Panc-1 cells demonstrated increased apoptosis with decreased viability after treatment with cetuximab-conjugated AuNPs and RF field exposure (P = 0.00005). Differences in xenograft volumes were observed within 2 weeks of initiating therapy. Cetuximab- and PAM4-conjugated AuNPs demonstrated RF field–induced destruction of Panc-1 and Capan-1 pancreatic carcinoma xenografts after 6 weeks of weekly treatment (P = 0.004 and P = 0.035, respectively). There was no evidence of injury to murine organs. Cleaved caspase-3 and necrosis were both increased in treated tumors. Conclusions: This study demonstrates a potentially novel cancer therapy by noninvasively inducing intracellular hyperthermia with targeted AuNPs in an RF field. While the therapy is dependent on the specificity of the targeting antibody, normal tissues were without toxicity despite systemic therapy and whole-body RF field exposure. Clin Cancer Res; 16(23); 5712–21. ©2010 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Tabernero, J., Van Cutsem, E., Díaz-Rubio, E., Cervantes, A., Humblet, Y., André, T., Van Laethem, J.-L., Soulié, P., Casado, E., Verslype, C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.2183 · Cited by 337
PAM4-Reactive MUC1 Is a Biomarker for Early Pancreatic Adenocarcinoma
Gold, D. V., Karanjawala, Z., Modrak, D. E., Goldenberg, D. M., & Hruban, R. H. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1488 · Cited by 93
Cited by
Recent Progress in Cancer Thermal Therapy Using Gold Nanoparticles
Abadeer, N. S., & Murphy, C. J. (2016) · The Journal of Physical Chemistry C · doi:10.1021/acs.jpcc.5b11232 · Cited by 919
Cancer active targeting by nanoparticles: a comprehensive review of literature
Bazak, R., Houri, M., El Achy, S., Kamel, S., & Refaat, T. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1767-3 · Cited by 756
Inorganic nanoparticles for cancer imaging and therapy
Huang, H.-C., Barua, S., Sharma, G., Dey, S. K., & Rege, K. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.06.004 · Cited by 618
Gold Nanoparticles in Cancer Treatment
Sztandera, K., Gorzkiewicz, M., & Klajnert-Maculewicz, B. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00810 · Cited by 607
Nanooncology: The future of cancer diagnosis and therapy
Thakor, A. S., & Gambhir, S. S. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21199 · Cited by 588
Metadata
- Authors
- Glazer, E. S., Zhu, C., Massey, K. L., Thompson, C. S., Kaluarachchi, W. D., Hamir, A. N., & Curley, S. A.
- Venue
- Clinical Cancer Research
- Published
- 2010-12-01
- Volume
- 16
- Issue
- 23
- Pages
- 5712-5721
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2115517594
- Cited by
- 161
- References
- 3
- FWCI
- 8.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Noninvasive Radiofrequency Field Destruction of Pancreatic Adenocarcinoma Xenografts Treated with Targeted Gold Nanoparticles. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-10-2055
- The paper
- Glazer, E. S., Zhu, C., Massey, K. L., Thompson, C. S., Kaluarachchi, W. D., Hamir, A. N., & Curley, S. A. (2010). Noninvasive Radiofrequency Field Destruction of Pancreatic Adenocarcinoma Xenografts Treated with Targeted Gold Nanoparticles. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-10-2055
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.